FORGOT YOUR DETAILS?

Reading Time: 2 minutes

journal_logoThe use of Saccharomyces Boulardii as a therapeutic intervention in people with alterations in their microbiota and local immune responses has been explored for over 50 years. The multiple points of action this simple yeast initiates in terms of mucosal barrier function and immune competence has made it an attractive and safe product for many clinicians. This study published in Jun 2014 in the American Society for Microbiology explores its role in a mouse model, but opens some interesting prospects for human health.[1]

Reading Time: 2 minutes

Saccharomyces is a non-colonising yeast used for the last 70 plus years as a therapeutic agent for the relief and management of gastrointestinal distress. Whilst its community use as a by-product of lychee fermentation was well understood in indo china and other nations, in particular for the relief of choleric dysentery it was after Henri Boulard set up the French pharmaceutical company to exploit its potential that studies began. So the recent publication (July 2014) of a review paper in the well known journal Pediatrics is a helpful means of qualifying its use in the paediatric population[1]

TOP